Let’s reassess the active stocks with an eye toward BPMX stock. Just how should we respond to Friday’s drubbing? Is the mighty fruit now destined to decay? Or is this a mere bruising and nothing more? On 08 February, shares of BioPharmX Corporation (NYSE:BPMX) closed lower after a volatile session. The shares dropped -0.01 points or -4.28 percent at $0.1 with a light trade volume of 2.908 million shares. After opening the session at $0.11, the shares went as high as $0.11 and as low as $0.1, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $22.9 million and now has 222.33 million shares outstanding. BioPharmX Corporation (BPMX) stock has lost -20.65 percent of market value in 21 trading days.
BPMX stock has a trailing 3-year beta of 0.2, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.04 a share in the trailing twelve months. The stock’s value has fallen -4.54 percent year to date (YTD) against a decline of -41.64 percent in 12 month’s time. The company’s shares still trade -72.54 percent away from its 1-year high of $0.38 and 106 percent up from 52-week low of $0.05. The average consensus rating on the company is 0, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
BioPharmX Corporation (BPMX) will probably climb -100 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $1 price as 12-month high target. This represents a whopping 900 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $0.7, which represents a return potential of 600 percent when compared to the closing price of the stock of $0.1 on Friday, February 08. The lowest price target for the stock is $0.4 — slightly more than 300 percent from BPMX’s current share price.
History has shown that shares in BioPharmX Corporation have gone down on 8 different earnings reaction days and are predicted to add 0.1 percent when the company reports upcoming earnings.
Let’s take a look at some insider activity at BioPharmX Corporation (NYSE:BPMX) and see the pattern. The earliest insider trade took place on 01/23/2019. Krammer Anja B parted with a total of 115.87 thousand shares of company at average share price of $0.11. The total for the sales was set at $12.75 thousand. After this transaction, the Director account balance stood at 1.88 million shares. The stock lost -9.09 percent since that insider sale. On 10/22/2018, Morlock Stephen, Director, sold 1.13 million shares at a price per share of $0.18. This removed 202.5 thousand shares from the insider’s fortune and the stock saw a -44.44 percent retreat in value since the news became public. This transaction left 0 thousand shares in the Director account.
On 10/12/2018, Director Krammer Anja B performed a sale transaction worth $95 thousand. This sale at $0.19 each has eliminated 500 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -47.37 percent decrease since the transaction was reported. The insider now is left with 2 million shares remaining in the account. Tierney David S, who performs the CEO job, bought 100 thousand shares for $20 thousand. The acquisition occurred on 09/19/2018 was priced at $0.2 per share. The share price plunged -50 percent since the reporting date. Tierney David S now left with a stake of 7.5 million BPMX stock worth $750 thousand after the insider buying.
The stock is currently hovering around the first support level of $0.1. Below this, the next support is placed in the zone of $0.09. Till the time, the BPMX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 40.04 on daily chart, which may remain a cause for concern. If the price breaks below $0.09 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.11 mark may result into a pull-back move towards $0.11 level.
Further, it is sporting a 322.54 on the Price-to-Sales ratio. Compare this with the industry average P/S of 51.22.